Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic tests, including FebriDx and ViraDx, and the LEELU READER platform. Its point-of-care technologies are supported by global distribution channels.

MST Access has published a research report on Lumos Diagnostics Limited.

FebriDx has surpassed 100 healthcare locations across 18 states in the United States

Announcements released to the ASX by Lumos Diagnostics (ASX:LDX).

Lumos Diagnostics has announced further progress in the U.S. commercialisation of FebriDx across its priority top-100 urgent care target list.

Lumos Diagnostics offers employment opportunities and specializes in rapid point-of-care diagnostics.

Lumos Diagnostics has recruited a specialized team focused on the point-of-care diagnostics industry. The page covers its team, products, services, investment opportunities, news, and contact information.

Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic tests to help healthcare professionals diagnose and manage medical conditions. It offers customized assay development and manufacturing services and proprietary digital reader platforms.

The page provides contact details for product, service, and investor inquiries, including addresses, phone numbers, and email contacts for Lumos Diagnostics’ US headquarters and AU corporate office.

Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic tests. The page covers its team, products, services, investment opportunities, news, and point-of-care work.

Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic tests. The page covers its team, products, services, investment opportunities, news, and point-of-care work.

Lumos Diagnostics develops, manufactures, and distributes point-of-care diagnostic technologies and offers custom services and support to the healthcare industry. It is listed on the ASX (ASX:LDX).